



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/688,676
Filing Date	17 October 2003
First Named Inventor	YANNI, John M., et al.
Art Unit	1632
Examiner Name	ANDOP SINGH
Attorney Docket Number	2394 US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If known)				
88						

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³	
		Country Code ⁴ Number ⁴ Kind Code ⁵ (if known)					
	A20						
	A21						
	A22						
	A23						
	A24						
	A25						


Examiner
SignatureDate
Considered

8-26-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/688,676
Filing Date	17 October 2003
First Named Inventor	YANNI, John M., et al.
Art Unit	1632
Examiner Name	ANOO P SINGH
Attorney Docket Number	2394 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ap	D1	Nakamura et al., "Gefamate Stimulates Secretion of Mucin-Like Glycoproteins by Corneal Epithelium in Vitro and Protects Corneal Epithelium from Desiccation in Vivo", EXPERIMENTAL EYE RESEARCH 65:569-574 (1997)	
ap	D2	Shappell et al., "15-Lipoxygenase-2 (15-LOX-2) Is Expressed in Benign Prostatic Epithelium and Reduced in Prostate Adenocarcinoma", AMER. J. PATH. 155(1):235-245 (1999)	
ap	D3	Shappell et al., "15-Lipoxygenase-2 Expression in Benign and Neoplastic Sebaceous Glands and Other Cutaneous Adnexa", J. INVESTIGATIVE DERMATOLOGY. 117(1):36-43 (2001)	
ap	D4	Shine and McCulley, "Keratoconjunctivitis Sicca Associated With Meibomian Secretion Polar Lipid Abnormality", ARCHIVES OF OPHTHALMOLOGY 116(7):849-52 (1998)	
ap	D5	Stechschulte et al., "Rapid Ocular Angiogenic Control via Naked DNA Delivery to Cornea", INVEST. OPHTHALMOL. VIS. SCI. 42(9):1975-1979 (2001)	
ap	D6	Watanabe et al., "Human Corneal and Conjunctival Epithelia Produce a Mucin-like Glycoprotein for the Apical Surface", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE 36(2):337-344 (1995)	
ap	D7	Yanni et al., "Effect of Intravenously Administered Lipoxygenase Metabolites on Rat Tracheal Mucous Gel Layer Thickness", INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY 90:307-309 (1989)	

Examiner Signature		Date Considered	8/26/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/688,676
Filing Date	17 October 2003
First Named Inventor	YANNI, John M., et al.
Art Unit	1632
Examiner Name	ANOO P SINGH
Attorney Docket Number	2394 US

Sheet

3

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ap	C1	Brash et al., "Discovery of a second 15S-lipoxygenase in humans", PROC. NATL. ACAD. SCI. USA 94:6148-6152 (1997)	
ap	C2	Dartt et al., "Vasoactive Intestinal Peptide-Stimulated Glycoconjugate Secretion from Conjunctival Goblet Cells", EXPERIMENTAL EYE RESEARCH 63:27-33, (1996)	
ap	C3	Dilly et al., "Surface changes in the anaesthetic conjunctiva in man, with special reference to the production of mucus from a non-goblet-cell source", BRITISH JOURNAL OF OPHTHALMOLOGY 65:833-842 (1981)	
ap	C4	Greiner et al., "Mucus Secretory Vesicles in Conjunctival Epithelial Cells of Wearers of Contact Lenses", ARCHIVES OF OPHTHALMOLOGY 98:1843-1846 (1980)	
ap	C5	Hsi et al., Evaluation of the activity and localization of 15-Lipoxygenase-1 after introduction into human colorectal carcinoma Caco-2 cells, PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS 64(4 & 5):217-225 (2001)	
ap	C6	Hsi et al., "Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate", THE JOURNAL OF BIOLOGICAL CHEMISTRY 277(43):40549-40556 (2002)	
ap	C7	Lemp, "Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes", The CLAO Journal, 21(4):221-232 (1995)	
ap	C8	Liminga and Oliw, "Qualitative and Quantitative Analysis of Lipoxygenase Products in Bovine Corneal Epithelium by Liquid Chromatography-Mass Spectrometry with an Ion Trap", LIPIDS 35(2):225-232 (2000)	
ap	C9	Marom et al., "Human Airway Monohydroxyeicosatetraenoic Acid Generation and Mucus Release", JOURNAL OF CLINICAL INVESTIGATION 72:122-127 (1983)	
ap	C10	McCulley and Shine, "Tear Film Structure and Dry Eye", Contactologia, 20(4):145-49 (1998)	

Examiner
Signature

[Signature]

Date
Considered

8-26-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.